



Application Serial No. 10/603,094
Response to Office Action Dated September 19, 2006
Page 2

Amendments to the Claims:

1. (Original) A cytomegalovirus vaccine which comprises a fusion peptide composed of a T helper epitope fused to a CMV CTL epitope peptide.
2. (Previously presented) A cytomegalovirus vaccine of claim 1 wherein said T helper epitope is PADRE (SEQ ID NO:2).
3. (Original) A cytomegalovirus vaccine of claim 1 wherein said T helper epitope is a tetanus epitope.
4. (Previously presented) A cytomegalovirus vaccine of claim 3 wherein said tetanus epitope is selected from the group consisting of tetanus heavy chain (590-603), tetanus heavy chain (615-629), tetanus heavy chain (639-652) (SEQ ID NO:4), tetanus heavy chain (830-843) (SEQ ID NO:3), and tetanus heavy chain (947-967).
5. (Currently amended) A cytomegalovirus vaccine of claim 1 wherein said CMV pp65 CTL epitope peptide is selected from the group consisting of pp65₁₃₋₂₄ (SEQ ID NO:15), pp65₁₈₆₋₁₉₆ (SEQ ID NO:16), pp65₁₈₈₋₁₉₅ (SEQ ID NO:17), pp65₂₆₅₋₂₇₅ (SEQ ID NO:18), pp65₃₆₃₋₃₇₃ (SEQ ID NO:19), pp65₃₆₉₋₃₇₉ (SEQ ID NO:20), pp65₃₆₇₋₃₇₉ (SEQ ID NO:21), pp65₄₉₅₋₅₀₃ (SEQ ID NO:1) and pp65₄₁₇₋₄₂₆ (SEQ ID NO:22).
6. (Previously presented) A cytomegalovirus vaccine of claim 5 wherein said CMV pp65 CTL epitope is pp65₄₉₅₋₅₀₃ (SEQ ID NO:1).

7. (Original) A cytomegalovirus vaccine of claim 1 which further comprises a DNA adjuvant.
8. (Currently amended) A cytomegalovirus vaccine of claim 6 7 wherein said DNA adjuvant is selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
9. (Original) A cytomegalovirus vaccine of claim 1 which further comprises a pharmaceutically acceptable carrier.
10. (Original) A fusion peptide comprising a T helper epitope fused to a CMV CTL epitope peptide.
11. (Previously presented) A fusion peptide of claim 10 wherein said T helper epitope is PADRE (SEQ ID NO:2).
:
12. (Original) A fusion peptide of claim 10 wherein said T helper epitope is a tetanus epitope.
13. (Previously presented) A fusion peptide of claim 10 wherein said tetanus epitope is selected from the group consisting of tetanus heavy chain (590-603), tetanus heavy chain (615-629), tetanus heavy chain (639-652) (SEQ ID NO:4), tetanus heavy chain (830-843) (SEQ ID NO:3), and tetanus heavy chain (947-967).
14. (Withdrawn) A method of modifying the immune response of a mammal to CMV comprising administering an effective amount of a vaccine of claim 1.